DRG Market Assessment reports

Clarivate Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…

Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States and Europe. The majority of…

Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and…

Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to…

The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years…

The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and…

Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs),…

Drug treatment of glaucoma focuses on reducing/controlling intraocular pressure and preserving visual function. Given the availability of multiple drug classes—i.e., prostaglandin analogues, beta…

Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP), which left untreated can lead to damage of the optic nerve and eventual…

Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP) resulting from the blockage or decreased drainage of the aqueous humor…